FDA
-
-
-
-
-
-
-
Provectus Biopharmaceuticals Announces Publication of In Vitro Data from Research on Oral Delivery of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
-
-
-
-
-
-
-
Provectus Biopharmaceuticals Announces Oral Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Checkpoint-Refractory Advanced Cutaneous Melanoma at Melanoma Brid
-
-
-
-
-
-
-
Provectus Biopharmaceuticals Announces Presentation of Preliminary Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual C
-
-
-
-
-
-
-
Provectus Biopharma (PVCT) Reports Publication of Updated Data from Metastatic Neuroendocrine Phase 1 PV-10 Study
-
-
-
-
-
-
-
Provectus Announces PV-10® Abstract Accepted for Presentation at Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting
-
-
-
-
-
-
-
Provectus Names Frank Akers, PhD to Company’s Strategic Advisory Board
-
-
-
-
-
-
-
Provectus Biopharmaceuticals Announces Acceptances of PV-10 Poster Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
-
322,520 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

